ACCOLADE INC (ACCD)

US00437E1029 - Common Stock

9.25  +0.08 (+0.87%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ACCOLADE INC

NASDAQ:ACCD (4/19/2024, 10:28:10 AM)

9.25

+0.08 (+0.87%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Providers & Services
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap716.04M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ACCD Daily chart

Company Profile

Accolade, Inc. engages in the provision of technology-enabled health and benefits solutions. The company is headquartered in Plymouth Meeting, Pennsylvania and currently employs 2,370 full-time employees. The company went IPO on 2020-07-02. Its customers are primarily employers that deploy Accolade solutions in order to provide employees and their families with a single place to turn for their health, healthcare, and benefits needs. The company also offers medical opinion services to commercial customers and virtual primary care and mental health support. Its platform, True Health Engine, combines open, cloud-based intelligent technology with multimodal support from a team of empathetic and knowledgeable Accolade Health Assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians. Its offerings include Accolade Expert MD, Accolade Care, Plus and Connect and Accolade One.

Company Info

ACCOLADE INC

660 W. Germantown Pike Suite 500

Plymouth Meeting PENNSYLVANIA 98101

P: 16108342989

CEO: Rajeev Singh

Employees: 2370

Website: https://www.accolade.com

ACCD News

News Image7 days ago - Market News VideoRelative Strength Alert For Accolade
News Imagea month ago - Market News VideoRelative Strength Alert For Accolade
News Image2 months ago - Accolade, Inc.Accolade To Present at Upcoming Investor Conferences

SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the following upcoming investor...

News Image2 months ago - InvestorPlaceAlabama’s Fertility Ruling Raises Challenges for Stocks of Fertility Benefits Providers

The recent Alabama State Supreme Court ruling on frozen embryos could have national repercussions. Here's what you need to know about it.

News Image2 months ago - Seeking AlphaProgyny stock slips after Alabama fertility ruling (NASDAQ:PGNY)

Progyny (PGNY) and Accolade (ACCD) drop after the Alabama Supreme Court ruled that frozen embryos can be considered children. Read more here.

News Image3 months ago - Market News VideoCommit To Buy Accolade At $7.50, Earn 11.2% Annualized Using Options

ACCD Twits

Here you can normally see the latest stock twits on ACCD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example